R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

Income Statement

Earnings Waterfall
R&G PharmaStudies Co Ltd

Revenue
738.4m CNY
Cost of Revenue
-447.5m CNY
Gross Profit
291m CNY
Operating Expenses
-172m CNY
Operating Income
119m CNY
Other Expenses
16.1m CNY
Net Income
135.1m CNY

Income Statement
R&G PharmaStudies Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024
Revenue
Revenue
608
N/A
635
+4%
640
+1%
634
-1%
638
+1%
628
-1%
493
-22%
721
+46%
537
-26%
738
+38%
Gross Profit
Cost of Revenue
(375)
(393)
(401)
(400)
(403)
(401)
(316)
(434)
(330)
(447)
Gross Profit
233
N/A
242
+4%
239
-1%
235
-2%
235
+0%
227
-3%
177
-22%
287
+62%
207
-28%
291
+41%
Operating Income
Operating Expenses
(121)
(125)
(121)
(121)
(127)
(123)
(89)
(144)
(122)
(172)
Selling, General & Administrative
(81)
(83)
(78)
(77)
(80)
(81)
(61)
(102)
(86)
(120)
Research & Development
(40)
(44)
(46)
(48)
(49)
(51)
(41)
(51)
(41)
(55)
Depreciation & Amortization
(3)
(1)
(1)
0
(3)
0
0
(3)
0
0
Other Operating Expenses
3
3
5
5
5
9
13
12
6
4
Operating Income
112
N/A
116
+4%
118
+2%
113
-4%
108
-5%
104
-4%
88
-15%
143
+62%
85
-40%
119
+39%
Pre-Tax Income
Interest Income Expense
1
2
9
16
21
27
23
39
26
36
Non-Reccuring Items
(0)
0
0
(0)
(0)
0
(0)
(0)
(0)
(0)
Total Other Income
0
0
0
(0)
0
(0)
(0)
(0)
0
(0)
Pre-Tax Income
114
N/A
118
+4%
127
+8%
129
+2%
129
0%
130
+1%
111
-15%
182
+65%
111
-39%
155
+39%
Net Income
Tax Provision
(13)
(14)
(15)
(15)
(15)
(15)
(12)
(20)
(11)
(19)
Income from Continuing Operations
100
104
112
114
114
116
98
163
100
136
Income to Minority Interest
(1)
(2)
(2)
(2)
(1)
(0)
(0)
(0)
(0)
(1)
Net Income (Common)
99
N/A
103
+4%
110
+7%
112
+2%
114
+1%
116
+2%
98
-15%
163
+65%
100
-39%
135
+36%
EPS (Diluted)
1.03
N/A
1.71
+66%
3.67
+115%
1.87
-49%
1.18
-37%
1.92
+63%
1.02
-47%
1.69
+66%
1.04
-38%
1.41
+36%

See Also

Discover More